Amicogen, Inc. Wins 'European Patent,' Targets Entry into Global Antibiotic Production Lines by 2027

[Financial News]  Amicogen, Inc. is expanding its China-focused antibiotic enzyme business into Europe and Japan. A decision to register a European patent for an enzyme used to produce a next-generation antibiotic intermediate has laid the groundwork for entering global markets. Market attention is shifting beyond securing the patent to whether the technology can be adopted on overseas pharmaceutical companies' production lines and generate visible revenue.
According to the company on the 19th, Amicogen, Inc. recently received a decision to register a European patent for CX, a first-stage enzyme used in next-generation 7-ACA synthesis. The company has expanded the scope of its technology protection to Europe, following Korea, the United States, China and Japan. Patent examination is also underway in India.
7-ACA is a key intermediate used in the manufacture of cephalosporin antibiotics. According to the company, the upgraded CX enzyme can improve production efficiency by increasing activity and stability compared with existing products.
Amicogen, Inc. is currently conducting pilot production tests with a European company specializing in antibiotics. It is also pursuing production validation with Japanese pharmaceutical and fine chemicals companies.
The goal is to apply the CX enzyme on customers' commercial production lines in 2027. The key question is whether the company can move beyond its existing China-focused supply structure and diversify its global customer base.
The restructuring of essential-medicine supply chains amid geopolitical tensions is also seen as an opportunity. As global pharmaceutical companies place equal importance on the reliability of raw material sourcing and production efficiency, the potential use of enzyme-based manufacturing technologies is coming into focus.
An industry insider in the biotech sector said, "Securing a patent is part of building a technological barrier to entry, and what has a tangible impact on corporate value is whether overseas customers adopt the technology for mass production," adding, "The results of production validation in Europe and Japan could be a turning point for future revenue growth."
Amicogen, Inc. CEO Park Cheol added, "We will successfully complete production validation with companies in Europe and Japan and achieve our goal of applying the technology on commercial production lines in 2027," and, "By combining AI with next-generation biotechnology, we will expand our global business base." 


[email protected] Kim Gyeong-a Reporter